North China Pharmaceutical Company.Ltd (SHA:600812)

SHA:600812 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	8,236	9,488	8,870	9,780	10,981	20,452
Market Cap Growth	-21.82%	6.96%	-9.30%	-10.94%	-46.31%	21.87%
Enterprise Value	19,344	20,188	19,926	20,598	20,895	30,116
Last Close Price	4.80	5.49	5.11	5.62	6.31	11.64

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	66.75	51.83	69.85	1999.79	-	1092.06
Forward PE	-	53.18	40.53	40.53	40.53	40.53
PS Ratio	1.01	1.03	0.90	0.97	1.05	1.97
PB Ratio	1.20	1.38	1.33	1.56	1.76	2.91
P/TBV Ratio	3.31	3.81	3.37	2.93	3.01	4.32
P/FCF Ratio	12.23	14.95	19.92	24.37	24.14	40.68
P/OCF Ratio	6.66	8.06	7.21	9.55	10.93	19.47

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EV/Sales Ratio	2.36	2.18	2.02	2.04	1.99	2.90
EV/EBITDA Ratio	13.02	13.31	13.73	16.15	15.51	24.60
EV/EBIT Ratio	37.45	32.19	30.24	38.40	32.92	50.18
EV/FCF Ratio	28.74	31.82	44.74	51.34	45.94	59.90

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	1.59	1.63	1.72	1.78	1.77	1.96
Debt / EBITDA Ratio	7.36	7.16	7.52	7.88	7.81	10.57
Debt / FCF Ratio	16.25	17.68	25.71	27.78	24.29	27.40
Net Debt / Equity Ratio	1.42	1.41	1.47	1.62	1.50	1.21
Net Debt / EBITDA Ratio	6.74	6.38	6.74	7.97	6.95	6.92
Net Debt / FCF Ratio	14.50	15.25	21.98	25.32	20.59	16.85
Asset Turnover	0.38	0.43	0.47	0.48	0.46	0.43
Inventory Turnover	2.39	2.59	2.63	2.69	2.87	2.76
Quick Ratio	0.51	0.45	0.50	0.49	0.49	0.70
Current Ratio	0.76	0.66	0.75	0.78	0.72	0.89
Return on Equity (ROE)	2.74%	3.80%	3.32%	0.79%	-10.25%	0.50%
Return on Assets (ROA)	1.51%	1.83%	1.94%	1.59%	1.72%	1.54%
Return on Invested Capital (ROIC)	2.15%	2.74%	2.78%	1.04%	4.08%	1.08%
Return on Capital Employed (ROCE)	4.90%	7.00%	6.30%	5.00%	7.20%	5.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 9, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Earnings Yield	1.50%	1.93%	1.43%	0.05%	-6.28%	0.09%
FCF Yield	8.17%	6.69%	5.02%	4.10%	4.14%	2.46%
Dividend Yield	0.74%	0.64%	0.59%	0.18%	-	0.52%
Payout Ratio	346.28%	225.53%	369.37%	10195.21%	-	3987.68%
Buyback Yield / Dilution	0.05%	0.31%	-5.27%	4.92%	-0.70%	-4.96%
Total Shareholder Return	0.79%	0.95%	-4.69%	5.10%	-0.70%	-4.44%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error